Last reviewed · How we verify

Yong Seog Oh — Portfolio Competitive Intelligence Brief

Yong Seog Oh pipeline: 0 marketed, 0 filed, 3 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 3 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Continuous heparin infusion Continuous heparin infusion phase 3 Anticoagulant Thrombin (Factor IIa), Factor Xa, Antithrombin III Cardiovascular
Adenosine arm Adenosine arm phase 3 Adenosine receptors (A1, A2A, A2B, A3)
Intermittent heparin infusion Intermittent heparin infusion phase 3 Anticoagulant Thrombin (Factor IIa), Factor Xa, Antithrombin III Cardiovascular

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  2. Beijing Anzhen Hospital · 1 shared drug class
  3. Beijing Chao Yang Hospital · 1 shared drug class
  4. Beijing Suncadia Pharmaceuticals Co., Ltd · 1 shared drug class
  5. Boston Scientific Corporation · 1 shared drug class
  6. CCRF Consulting Co., Ltd. · 1 shared drug class
  7. Deutsches Herzzentrum Muenchen · 1 shared drug class
  8. Anemia Working Group Romania · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Yong Seog Oh:

Cite this brief

Drug Landscape (2026). Yong Seog Oh — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/yong-seog-oh. Accessed 2026-05-16.

Related